Conditions: Pulmonary Disease, Chronic Obstructive
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 122
Healthy volunteers: no

Brief summary:
The study is intended to characterize the lung function profile of BI1744 in Chronic Obstructive Pulmonary Disease (COPD) patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period. Each patient will receive all four treatments.

Detailed description:

Arms:
arm 1: Low dose inhaled orally once daily from Respimat inhaler arm 2: High dose inhaled orally once daily from Respimat inhaler arm 3: 18 mcg inhaled once daily from HandiHaler arm 4: Olodaterol placebo and/or Tiotropium placebo inhaled once daily

Interventions: intervention 1: Olodaterol (BI1744) Low intervention 2: Olodaterol (BI1744) High intervention 3: Tiotropium 18 mcg intervention 4: Placebo (for Olodaterol (BI1744)l) intervention 5: Placebo (for Tiotropium)
Intervention descriptions: intervention 1: Low dose inhaled orally once daily from Respimat inhaler intervention 2: High dose inhaled orally once daily from Respimat inhaler intervention 3: 18 mcg inhaled once daily from HandiHaler intervention 4: Placebo (olodaterol low and high dose) delivered by Respimat intervention 5: Placebo (Tiotropium 18 mcg) delivered by HandiHaler

Protocol document: